Stago at WHX Labs Dubai 2026: Four days of innovation and networking

Back to list

Stago teams from Saudi Arabia, Turkey, Dubai, and headquarters participated in WHX Labs Dubai 2026, formerly known as Medlab Middle East. Held at the Dubai World Trade Centre, the event brought together over 35,000 professionals from 180 countries.
Stago teams from Saudi Arabia, Turkey, Dubai, and headquarters participated in WHX Labs Dubai 2026, formerly known as Medlab Middle East. Held at the Dubai World Trade Centre, the event brought together over 35,000 professionals from 180 countries.

Communication of March 4, 2026

Back to list

Dear valued Partner,
We are pleased to share an important update regarding Stago's future.

Stago has entered into an exclusive negotiations with ARCHIMED, a healthcare-focused investment firm and La Caisse, also active in the healthcare sector, to support the next phase of our growth. 

This step reflects a strategic decision to further strengthen Stago's long-term growth while preserving what has always defined us: scientific excellence, reliability, deep expertise in hemostasis, and a strong commitment to customer partnerships.

Stago webinar: Emerging biomarker for thrombotic risk stratification in coronary artery disease

Back to list

Clinicians, clinical pathologists, researchers, and clinical laboratory staff will have the opportunity to deepen their knowledge of the role of TF-positive platelets in arterial thrombosis and CAD progression, as well as their potential to improve thrombotic risk stratification beyond traditional models.
Clinicians, clinical pathologists, researchers, and clinical laboratory staff will have the opportunity to deepen their knowledge of the role of TF-positive platelets in arterial thrombosis and CAD progression, as well as their potential to improve thrombotic risk stratification beyond traditional models.

Stago enters into exclusive negotiations with ARCHIMED and La Caisse

Back to list

PRESS RELEASE: December 11, 2025

The Stago Group, a global leader in diagnostics and a specialist in hemostasis, announced today that it has entered into exclusive negotiations with a consortium led by ARCHIMED, an investment fund dedicated to the healthcare sector, with a view to acquiring a majority stake in the group. La Caisse (formerly Caisse de dépôt et Placement du Québec) would invest alongside ARCHIMED as a minority investor.

 

Stago's 2025 CSR Report is online

Back to list

The Stago Group’s commitment to sustainability takes a new step forward with the release of our latest CSR report. More comprehensive, concrete, and forward-looking, it reflects the collective efforts of our international teams and subsidiaries, and the growing integration of CSR into our daily actions and long-term vision.
The Stago Group’s commitment to sustainability takes a new step forward with the release of our latest CSR report. More comprehensive, concrete, and forward-looking, it reflects the collective efforts of our international teams and subsidiaries, and the growing integration of CSR into our daily actions and long-term vision.

New Focus on Extracellular Vesicles

Back to list

This Focus leaflet illustrates how extracellular vesicles (EVs), once confined to basic research, are now on the path to becoming valuable tools in clinical diagnostics. This last issue has been coordinated by Professor Françoise Dignat-George, recipient of the ISTH Esteemed Career Award 2025.
This Focus leaflet illustrates how extracellular vesicles (EVs), once confined to basic research, are now on the path to becoming valuable tools in clinical diagnostics. This last issue has been coordinated by Professor Françoise Dignat-George, recipient of the ISTH Esteemed Career Award 2025.

New Practical Manual on Hemostasis and Thrombosis in special patient populations

Back to list

This new book is dedicated to the challenges of hemostasis and thrombosis in special patient populations, offering practical guidance for interpreting test results and improving patient care.
This new book is dedicated to the challenges of hemostasis and thrombosis in special patient populations, offering practical guidance for interpreting test results and improving patient care.

QUALIblood: Our new partner in advancing the diagnosis of thrombosis risk

Back to list

On 14 February 2025, QUALIblood and Diagnostica Stago formalised a strategic alliance focused on the development and future launch of a new reagent kit, nAPCsr – a thrombin generation test designed to assess thrombosis risk in women considering or currently using oestrogen-based hormonal treatments, particularly oral contraceptives.
On 14 February 2025, QUALIblood and Diagnostica Stago formalised a strategic alliance focused on the development and future launch of a new reagent kit, nAPCsr – a thrombin generation test designed to assess thrombosis risk in women considering or currently using oestrogen-based hormonal treatments, particularly oral contraceptives.

A new look for Stago's scientific posters 

Back to list

Sharing and deepening knowledge is essential if we are to become a benchmark in the field of blood diagnostics. With this in mind, six scientific posters have been updated and redesigned to offer more up-to-date and accurate content.
Sharing and deepening knowledge is essential if we are to become a benchmark in the field of blood diagnostics. With this in mind, six scientific posters have been updated and redesigned to offer more up-to-date and accurate content.
Subscribe to